Drugs / PPI-1019
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00100282 | May 2003 → Jun 2005 | Alzheimer disease | PRAECIS Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00100334 | Dec 2004 → Aug 2005 | Alzheimer disease | PRAECIS Pharmaceuticals Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PPI-1019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00100334 ↗ |
| Known as | APAN | “PPI-1019 (APAN)” NCT00100282 ↗1“PPI-1019 (APAN)” NCT00100334 ↗ |
| Route | Intravenous | “intravenously (IV)” NCT00100282 ↗ |